Integrated transcriptomics profile reveals the role of Gal-1 and miR-21 in intrahepatic cholangiocarcinoma progression
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2025
DOI: 10.1016/j.bbadis.2025.167882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025. Verfasst von Huasong Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, School of Medicine, Hunan Normal University, Changsha, China; State Key Laboratory of Experimental Hematology, …. Hauptthemen laut MEDLINE: Cholangiocarcinoma, MicroRNAs, Galectin 1, Bile Duct Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Department of Science and Technology of Hunan Province, Science Fund for Distinguished Young Scholars of Hunan Province, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (ICC) is a highly invasive liver tumor with a poor prognosis, arises from the intrahepatic bile ducts. It is the second most common type of liver cancer. Understanding the mechanisms driving ICC progression is crucial for identification of biomarkers and therapeutic targets. Galectin-1 (Gal-1), encoded by the LGALS1 gene, is known to be upregulated in various malignancies and plays a significant role in cancer progression. However, its underlying mechanisms in ICC have yet to be fully elucidated. The study employed RNA-seq analysis, western blot, cell migration, colony forming, EdU assay, qRT-PCR, luciferase assay and mIHC to investigate the expression pattern of Gal-1 in ICC and its role in the progression of the disease. Our findings revealed a significant upregulation of Gal-1 in ICC tissues. Notably, downregulation of Gal-1inhibited ICC cell proliferation and migration. Further, Gal-1 appears to promote ICC progression through miR-21/STAT3-related pathways, playing a critical role to the tumor microenvironment. These results suggest that Gal-1 may serve as a promising molecular diagnostic marker and therapeutic target for ICC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, School of Medicine, Hunan Normal University, Changsha, China; State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center…
- Department of Basic Medical Sciences, School of Medicine, Hunan Normal University, Changsha, China; Key Laboratory of Model Animals and Stem Cell Biology of Hunan Province, School of Medicine, Hunan Normal University, C…
- Biliary Tract Surgery Laboratory, Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China; Hunan Research Center of Biliary Dise…
Förderung
- Department of Science and Technology of Hunan Province
- Science Fund for Distinguished Young Scholars of Hunan Province
- Hunan Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Yu, H., Duan, H., He, R., Tian, Y., Jiang, J., Xiao, F., Liu, Q., Liu, J., Li, H., & Yu, X. (2025). Integrated transcriptomics profile reveals the role of Gal-1 and miR-21 in intrahepatic cholangiocarcinoma progression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2025.167882
Vancouver
Yu H, Duan H, He R, Tian Y, Jiang J, Xiao F, et al. Integrated transcriptomics profile reveals the role of Gal-1 and miR-21 in intrahepatic cholangiocarcinoma progression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025. doi:10.1016/j.bbadis.2025.167882
BibTeX
@article{Yu2025,
author = {Yu, Huasong and Duan, Huahong and He, Ruiqi and Tian, Yu and Jiang, Jiayang and Xiao, Fen and Liu, Qiao and Liu, Jie and Li, Hao and Yu, Xing},
title = {Integrated transcriptomics profile reveals the role of Gal-1 and miR-21 in intrahepatic cholangiocarcinoma progression},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2025},
doi = {10.1016/j.bbadis.2025.167882}
}
EUVIMED